251,914 Shares in Nkarta, Inc. (NASDAQ:NKTX) Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC acquired a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 251,914 shares of the company’s stock, valued at approximately $1,489,000. Cubist Systematic Strategies LLC owned 0.51% of Nkarta as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. RA Capital Management L.P. grew its stake in Nkarta by 38.4% in the first quarter. RA Capital Management L.P. now owns 10,805,129 shares of the company’s stock valued at $116,803,000 after purchasing an additional 3,000,000 shares during the last quarter. SR One Capital Management LP lifted its position in Nkarta by 150.0% during the first quarter. SR One Capital Management LP now owns 3,333,333 shares of the company’s stock valued at $36,033,000 after acquiring an additional 2,000,000 shares during the last quarter. Commodore Capital LP acquired a new stake in Nkarta in the fourth quarter valued at approximately $18,018,000. Wasatch Advisors LP grew its holdings in Nkarta by 13.6% in the fourth quarter. Wasatch Advisors LP now owns 2,099,699 shares of the company’s stock worth $13,858,000 after purchasing an additional 251,795 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Nkarta by 26.0% during the first quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock worth $21,255,000 after purchasing an additional 405,753 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Insider Activity at Nkarta

In other Nkarta news, insider Alicia J. Hager sold 3,396 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $8.00, for a total value of $27,168.00. Following the sale, the insider now owns 103,819 shares in the company, valued at approximately $830,552. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 target price on shares of Nkarta in a research report on Wednesday, August 14th. Raymond James raised shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 price objective for the company in a research report on Wednesday, August 14th. Finally, HC Wainwright cut their price target on shares of Nkarta from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Nkarta presently has a consensus rating of “Buy” and a consensus price target of $18.20.

Nkarta Trading Down 6.9 %

Shares of NASDAQ NKTX opened at $4.21 on Wednesday. The company has a 50 day simple moving average of $5.47 and a two-hundred day simple moving average of $6.67. The stock has a market cap of $208.04 million, a price-to-earnings ratio of -1.79 and a beta of 0.81. Nkarta, Inc. has a 12 month low of $1.28 and a 12 month high of $16.24.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.15. Analysts forecast that Nkarta, Inc. will post -1.92 EPS for the current year.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.